PURPOSE: Breast cancer chemotherapy may cause unfavorable changes in physical functioning, body composition, psychosocial functioning, and quality of life (QOL). We evaluated the relative merits of aerobic and resistance exercise in blunting these effects. PATIENTS AND METHODS: We conducted a multicenter randomized controlled trial in Canada between 2003 and 2005 that randomly assigned 242 breast cancer patients initiating adjuvant chemotherapy to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their chemotherapy (median, 17 weeks; 95% CI, 9 to 24 weeks). Our primary end point was cancer-specific QOL assessed by the Functional Assessment of Cancer Therapy-Anemia scale. Secondary end points were fatigue, psychosocial functioning, physical fitness, body composition, chemotherapy completion rate, and lymphedema. RESULTS: The follow-up assessment rate for our primary end point was 92.1%, and adherence to the supervised exercise was 70.2%. Unadjusted and adjusted mixed-model analyses indicated that aerobic exercise was superior to usual care for improving self-esteem (P = .015), aerobic fitness (P = .006), and percent body fat (adjusted P = .076). Resistance exercise was superior to usual care for improving self-esteem (P = .018), muscular strength (P < .001), lean body mass (P = .015), and chemotherapy completion rate (P = .033). Changes in cancer-specific QOL, fatigue, depression, and anxiety favored the exercise groups but did not reach statistical significance. Exercise did not cause lymphedema or adverse events. CONCLUSION: Neither aerobic nor resistance exercise significantly improved cancer-specific QOL in breast cancer patients receivingchemotherapy, but they did improve self-esteem, physical fitness, body composition, and chemotherapy completion rate without causing lymphedema or significant adverse events.
RCT Entities:
PURPOSE:Breast cancer chemotherapy may cause unfavorable changes in physical functioning, body composition, psychosocial functioning, and quality of life (QOL). We evaluated the relative merits of aerobic and resistance exercise in blunting these effects. PATIENTS AND METHODS: We conducted a multicenter randomized controlled trial in Canada between 2003 and 2005 that randomly assigned 242 breast cancerpatients initiating adjuvant chemotherapy to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their chemotherapy (median, 17 weeks; 95% CI, 9 to 24 weeks). Our primary end point was cancer-specific QOL assessed by the Functional Assessment of Cancer Therapy-Anemia scale. Secondary end points were fatigue, psychosocial functioning, physical fitness, body composition, chemotherapy completion rate, and lymphedema. RESULTS: The follow-up assessment rate for our primary end point was 92.1%, and adherence to the supervised exercise was 70.2%. Unadjusted and adjusted mixed-model analyses indicated that aerobic exercise was superior to usual care for improving self-esteem (P = .015), aerobic fitness (P = .006), and percent body fat (adjusted P = .076). Resistance exercise was superior to usual care for improving self-esteem (P = .018), muscular strength (P < .001), lean body mass (P = .015), and chemotherapy completion rate (P = .033). Changes in cancer-specific QOL, fatigue, depression, and anxiety favored the exercise groups but did not reach statistical significance. Exercise did not cause lymphedema or adverse events. CONCLUSION: Neither aerobic nor resistance exercise significantly improved cancer-specific QOL in breast cancerpatients receiving chemotherapy, but they did improve self-esteem, physical fitness, body composition, and chemotherapy completion rate without causing lymphedema or significant adverse events.
Authors: Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Allison C Stover; Janet R Abrams Journal: J Cancer Surviv Date: 2010-05-08 Impact factor: 4.442
Authors: Lee W Jones; Yuanyuan Liang; Edith N Pituskin; Claudio L Battaglini; Jessica M Scott; Whitney E Hornsby; Mark Haykowsky Journal: Oncologist Date: 2011-01-06
Authors: Marilyn L Kwan; Barbara Sternfeld; Isaac Joshua Ergas; Allegra W Timperi; Janise M Roh; Chi-Chen Hong; Charles P Quesenberry; Lawrence H Kushi Journal: Breast Cancer Res Treat Date: 2011-09-28 Impact factor: 4.872
Authors: Kathryn H Schmitz; Andrea B Troxel; Andrea Cheville; Lorita L Grant; Cathy J Bryan; Cynthia R Gross; Leslie A Lytle; Rehana L Ahmed Journal: Contemp Clin Trials Date: 2009-01-08 Impact factor: 2.226